| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb66d9373d09efad73c142762f6dfb00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-20 |
| filingDate |
2004-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6632a73993ffee37bbbbd3cce16427f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_603ca4e9f61dae9b1524614d7f476820 |
| publicationDate |
2004-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2004162327-A1 |
| titleOfInvention |
Crystalline form of telmisartan sodium |
| abstract |
The invention relates to a crystalline sodium salt of 4′-[2-n-propyl-4-methyl-6-(1-methyl-benzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), processes for preparing it and the use thereof for preparing a pharmaceutical composition. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1719766-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009030057-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2296520-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10836745-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009227802-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7943781-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009124814-A1 |
| priorityDate |
2001-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |